Search the Newsreel

FDA grants fast track status to Aclaris’ lichen planus drug By Investing.com

Aclaris Therapeutics Inc. (NASDAQ:ACRS) has received Fast Track Designation from the FDA for its drug modzatinib (ATI-2138) to treat moderate to severe lichen planus. This designation will accelerate the development and review process for the drug, which addresses an unmet medical need as there …

Clarus Reports Second Quarter 2026 Results

Clarus Corporation (CLAR) Surpasses Q2 Earnings and Revenue Estimates

Clarus Corporation (CLAR) reported strong Q2 2026 earnings, beating Zacks Consensus Estimates for both EPS and revenue. The company posted adjusted earnings of $0.18 per share against an expected loss of $0.07, and revenues of $56.16 million, surpassing estimates by 8.96%. Despite underperforming the …

Kimberly-Clark (KMB) Beat On Earnings, Is The Stock Still Cheap?

Kimberly-Clark (KMB) reported an earnings beat in Q2 2026, driven by cost savings, despite a revenue miss and a lower 2026 outlook. The stock is currently trading at US$112.37, showing a recent rebound but remains undervalued compared to a fair value estimate of $117.00. …

Kimberly Clark (KMB) Stock Rebounds As Margin Pressure Clouds Value Case

CLAROS MORTGAGE TRUST, INC. : WELLS FARGO CUTS TARGET PRICE TO $1.75 FROM $2.5

Wells Fargo has lowered its target price for Claros Mortgage Trust, Inc. from $2.5 to $1.75. This adjustment indicates a revised outlook on the company's valuation by the financial institution. The article, originating from Reuters, highlights this specific change in analyst rating.

Why Aclara Resources Inc stock is skyrocketing today

ASX Penny Stocks Spotlight Clarity Pharmaceuticals And 2 More Compelling Picks

Earnings call transcript: Clarus tops Q2 2026 estimates as shares rise after hours

Clarus Corp. (CLAR) exceeded Q2 2026 earnings estimates, reporting $0.18 EPS on $56.2 million revenue, leading to a 6.82% rise in after-hours trading. The company's performance was boosted by its Outdoor segment and a one-time tariff refund, prompting a significant increase in its full-year …

Clarus declares $0.025 quarterly dividend

Clarus Corporation announced a regular quarterly cash dividend of $0.025 per share. The dividend is scheduled to be paid on August 26, 2026, to stockholders of record as of August 17, 2026. Clarus designs and develops equipment and lifestyle products for outdoor enthusiasts, sold …

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

Press Release: Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

This press release from Aclaris Therapeutics announces its financial results for the second quarter of 2026, alongside corporate and clinical updates. The report will likely detail key financial metrics, provide insights into their ongoing clinical trials, and offer a broader corporate overview for investors …

Aclaris Therapeutics reports Q2 2026 net loss of $21.5M, cash runway through 2028

Aclaris Therapeutics reported a Q2 2026 net loss of $21.5 million, with cash, cash equivalents, and marketable securities totaling $170.6 million as of June 30, 2026. The company expects its cash runway, bolstered by an additional $40.2 million from ATM sales, to fund operations …

Earnings Flash (ACRS) Aclaris Therapeutics, Inc. Reports Q2 Revenue $1.6M, vs. FactSet Est of $1.4M

Aclaris Therapeutics, Inc. (ACRS) announced its Q2 revenue of $1.6 million, surpassing the FactSet estimate of $1.4 million. The biopharmaceutical company also recently received Fast-Track Designation for its inflammation treatment, Modzatinib, and was added to several Russell and S&P indices. The company is engaged …

Earnings Flash (ACRS) Aclaris Therapeutics Posts Q2 Net Loss $0.15 a Share, vs. FactSet Est of $0.16 Loss

Empowered Funds LLC Cuts Stock Position in Kimberly-Clark Corporation $KMB

Empowered Funds LLC significantly reduced its stake in Kimberly-Clark Corporation by 58.6% in the first quarter, selling 37,181 shares and retaining 26,276 shares valued at $2.54 million. This comes as Kimberly-Clark reported mixed Q2 earnings, missing revenue and EPS estimates, though other institutional investors …

Clarivate Insider Sold Shares Worth $4,829,859, According to a Recent SEC Filing

An insider at Clarivate Plc reportedly sold shares valued at $4,829,859, as per a recent SEC filing. The article, published by MT Newswires, provides this financial transaction detail but restricts the full content to members. Clarivate Plc is a provider of transformative intelligence solutions …

Clarivate Scales Agentic AI Across Cortellis to Advance Drug Development

Expanded capabilities across Cortellis portfolio help life sciences organizations turn trusted intelligence into action and accelerate decision making across the research and development lifecycle LONDON, Aug. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the expansion …

Earnings To Watch: Claritev Corp (CTEV) Q2 2026 -- GF Value Sees 24% Upside

Clarus Q2 Earnings Call Highlights

Aclaris Therapeutics (ACRS) Earnings Date and Reports 2026 $ACRS

Kimberly-Clark Corp (KMB) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Andrew Miles Snyder Sells 2,489,618 Shares of Clarivate (NYSE:CLVT) Stock

Clarivate director Andrew Miles Snyder sold 2,489,618 shares of CLVT stock at an average price of $1.94, totaling approximately $4.83 million, reducing his direct ownership by 39.23%. This transaction occurred as Clarivate shares traded near their 52-week low and the company reported quarterly EPS …

Clarus Sets Aug. 26 Cash Payment Date for Stockholders

Clarus Corporation (NASDAQ: CLAR) announced that its board of directors has confirmed a regular quarterly cash dividend of $0.025 per share. The dividend will be paid on August 26, 2026, to stockholders of record as of August 17, 2026. This announcement provides shareholders with …

Earnings To Watch: Clarus (CLAR) Reports Q2 Results Tomorrow

Claros Mortgage Trust Is Maintained at Underweight by Wells Fargo

Wells Fargo has reiterated its "Underweight" rating on Claros Mortgage Trust. This indicates a continued cautious outlook from the investment bank regarding the company's stock performance.

Kimberly-Clark unveils proprietary alternative natural fiber innovation program

Kimberly-Clark has launched a proprietary innovation program focused on developing alternative natural fibers for hygiene products, with hesperaloe as a key component. This initiative aims to enhance product performance, improve sustainability, and reduce reliance on traditional forest-based fiber sources. The company is establishing a …

Aclaris Therapeutics (NASDAQ: ACRS) CSO gets shares, some withheld

Aclaris Therapeutics' Chief Scientific Officer, Roland Kolbeck, had 36,375 restricted stock units vest, converting into common shares on August 1, 2026. Of these, 12,385 shares were withheld for tax obligations at $5.20 per share. Kolbeck still holds 109,125 RSUs that will vest in future …

Arrowstreet Capital Limited Partnership Acquires Shares of 1,320,982 Clarivate PLC $CLVT

Arrowstreet Capital Limited Partnership recently acquired 1,320,982 shares of Clarivate PLC (NYSE:CLVT) worth approximately $3.34 million, marking a new position and a 0.21% stake in the company. Despite Clarivate beating analyst EPS estimates with $0.19, its revenue of $587.3 million fell short of expectations …

Is Kimberly Clark (KMB) Undervalued After Q2 Earnings And A Lowered 2026 Outlook?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Kimberly-Clark (KMB) is back in focus after second quarter 2026 earnings beat profit expectations but fell short on revenue, as management flagged ongoing profit …

Wells Fargo & Company Issues Pessimistic Forecast for Claros Mortgage Trust (NYSE:CMTG) Stock Price

Aclara Resources Inc (ARA) Earnings Preview — What to Watch Before the Report

Clarkson PLC (CKN.L) Stock Analysis: Navigating Strong Revenue Growth and Promising Ratings

How Investors Are Reacting To Kimberly-Clark (KMB) Mixed Q2 Results And New Hesperaloe Fiber Bet

Kimberly-Clark reported past second-quarter 2026 results showing sales of US$4,189 million versus US$4,163 million a year earlier, while net income fell to US$345 million from US$509 million, and also unveiled an alternative natural fiber program using the drought-resistant hesperaloe plant to support future sustainable …

Kimberly-Clark Aktie News: Kimberly-Clark schiebt sich am Abend vor

Kimberly-Clark tem recomendação elevada para compra pela Freedom Broker - Investing.com Brasil